...
首页> 外文期刊>Key Engineering Materials >A Novel Drug Delivery System for Bisphosphonates: Innovative Strategy for Local Treatment of Bone Resorption
【24h】

A Novel Drug Delivery System for Bisphosphonates: Innovative Strategy for Local Treatment of Bone Resorption

机译:双膦酸盐的新型药物输送系统:骨吸收局部治疗的创新策略

获取原文
获取原文并翻译 | 示例

摘要

One type of potent aminobisphosphonate (Zoledronate) has been chemically associated onto β-tricalcium phosphate [β-TCP] and calcium deficients apatite [CDA]. Two different association modes have been observed, according to the nature of the Calcium Phosphate [CaP] support and/or the initial concentration of the Zoledronate solution. β-TCP appears to promote Zoledronate-containing crystals formation. On the other hand, at concentrations < 0.05 mol.L~(-1) CDA seems to undergo chemisorption of the drug through a surface adsorption process, due to PO_3 for PO_4 exchange, which is well described by Freundlich equations. At concentrations > 0.05 mol.L~(-1), crystalline needles of a Zoledronate complex form onto the CDA surface. The ability of CDA to release Zoledronate, resulting in the inhibition of osteoclastic activity, was shown using a specific in vitro bone resorption model.
机译:一种有效的氨基双膦酸盐(唑来膦酸盐)已化学缔合在β-磷酸三钙[β-TCP]和钙缺乏磷灰石[CDA]上。根据磷酸钙[CaP]载体的性质和/或唑来膦酸盐溶液的初始浓度,已经观察到两种不同的缔合模式。 β-TCP似乎促进了含唑来膦酸盐的晶体的形成。另一方面,在浓度<0.05 mol.L〜(-1)下,由于PO_3交换PO_4,CDA似乎通过表面吸附过程发生了化学吸附,这在Freundlich方程中已得到很好的描述。当浓度> 0.05 mol.L〜(-1)时,唑来膦酸盐配合物的结晶针形成在CDA表面。使用特定的体外骨吸收模型显示了CDA释放唑来膦酸盐的能力,从而导致破骨活性的抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号